STOCK TITAN

Putnam BioRevolution ETF (SYNB) Stock Price, News & Analysis

SYNB NYSE
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
2 251 sessions, November 13, 2024 to November 13, 2025
Largest daily move
+7.5% close of April 9, 2025
1-year change
+2.1% closing prices, November 13, 2024 to November 13, 2025
1-month change
+3.5% closing prices, October 13, 2025 to November 13, 2025

Company Description

The ticker SYNB represents the Putnam BioRevolution ETF, an exchange-traded fund identified in public communications as Putnam BioRevolution ETF (SYNB). According to a Business Wire announcement issued by Franklin Templeton, the fund is scheduled to be liquidated and dissolved. The announcement explains that the liquidation is anticipated to occur on or about November 21, 2025, with related trading and order activity ceasing ahead of that date.

The Putnam BioRevolution ETF (SYNB) is associated with Franklin Templeton, which is described in the same announcement as a global investment management organization whose subsidiaries operate under the Franklin Templeton name. The communication notes that Franklin Templeton’s mission is to help clients achieve better outcomes through investment management expertise, wealth management and technology solutions, and that it offers capabilities in equity, fixed income, alternatives and multi-asset solutions through its specialist investment managers.

The liquidation plan for SYNB includes several key steps described in the announcement. Effective as of the close of business on October 24, 2025, the fund will no longer accept orders for the purchase of creation units. Effective as of the close of business on November 13, 2025, the fund will no longer accept redemption orders. Trading for the fund on NYSE Arca, Inc. (NYSE Arca) is expected to be suspended prior to market open on November 14, 2025.

Following the suspension of trading and the cessation of purchases and redemptions, the announcement states that, as soon as reasonably practicable on or after the liquidation date, the fund will liquidate its remaining assets after payment or provision for charges, taxes, expenses and liabilities. After any dividend determinations, the fund intends to distribute cash pro rata to all remaining shareholders as of the liquidation date who have not previously redeemed all of their shares. The announcement notes that proceeds of the liquidation are currently scheduled to be sent to shareholders on or about November 21, 2025, and that shareholders should consult their tax advisors about the tax implications of the liquidation.

Franklin Resources, Inc., which is identified with the NYSE ticker BEN in the same announcement, is described as a California-based company with subsidiaries operating as Franklin Templeton and serving clients in over 150 countries. The announcement highlights that Franklin Templeton brings extensive capabilities in equity, fixed income, alternatives and multi-asset solutions, and that it has many investment professionals and offices in major financial markets around the world. These details provide context for the asset management group responsible for the Putnam BioRevolution ETF (SYNB).

Because the fund is in the process of being liquidated and dissolved, SYNB should be understood in a historical and transitional context. The Business Wire announcement outlines a defined timeline for the end of trading, the halt of creation and redemption activity, and the distribution of liquidation proceeds to shareholders. Investors and observers reviewing SYNB as a symbol can use this information to understand that the fund is not being positioned for ongoing operation, but instead is moving through a planned wind-down process as described in the Franklin Templeton communication.

Stock Performance

$31.61
No recent trading
Last close: November 13, 2025
+2.1%
1 year to November 13, 2025

Putnam BioRevolution ETF (SYNB) closed at $31.61 on November 13, 2025. In the 12 months to November 13, 2025, the price gained 2.1%.

See what a $1,000 investment in SYNB would be worth today

Average down calculator for SYNB

SYNB Metrics & Rankings

Price returns through November 13, 2025. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Putnam BioRevolution ETF has 1 recent news article. Of the recent coverage, 0 articles coincided with positive price movement and 1 with negative movement. View all SYNB news →

SEC Filings

No SEC filings available for SYNB.

Frequently Asked Questions

Putnam BioRevolution ETF (SYNB) has no recent trading. Its last close was $31.61 on November 13, 2025.

SYNB is the ticker symbol for the Putnam BioRevolution ETF, identified in a Franklin Templeton Business Wire announcement as Putnam BioRevolution ETF (SYNB), an exchange-traded fund listed on NYSE Arca.

According to a Franklin Templeton announcement, the Putnam BioRevolution ETF (SYNB) is scheduled to be liquidated and dissolved. The communication describes a plan under which the fund will cease accepting certain orders, suspend trading on NYSE Arca, and then liquidate its remaining assets and distribute cash to shareholders.

The Franklin Templeton announcement states that, effective as of the close of business on October 24, 2025, the fund will no longer accept orders for the purchase of creation units, and effective as of the close of business on November 13, 2025, it will no longer accept redemption orders.

The announcement explains that trading for the Putnam BioRevolution ETF (SYNB) on NYSE Arca is expected to be suspended prior to market open on November 14, 2025.

Franklin Templeton’s announcement indicates that, after paying or providing for charges, taxes, expenses and liabilities and determining any dividends, the fund will liquidate its remaining assets and distribute cash pro rata to all remaining shareholders as of the liquidation date who have not previously redeemed all of their shares. Proceeds are scheduled to be sent on or about November 21, 2025.

The Business Wire announcement associates the Putnam BioRevolution ETF (SYNB) with Franklin Templeton, whose parent company is Franklin Resources, Inc. The announcement describes Franklin Templeton as a global investment management organization with subsidiaries operating under the Franklin Templeton name.

The announcement states that Franklin Templeton’s mission is to help clients achieve better outcomes through investment management expertise, wealth management and technology solutions. It notes that through its specialist investment managers, the company offers capabilities in equity, fixed income, alternatives and multi-asset solutions.

Yes. The Franklin Templeton announcement explicitly advises shareholders to consult their tax advisors about the tax implications of the liquidation of the Putnam BioRevolution ETF (SYNB).